

GET A LONG

Unravelling the **new role** of **Long Acting Injectables**
in **Schizophrenia** management

Budapest
7th April 2024
Hungarian Academy
of Science

LIVE EVENT

Under the patronage of



CULTURE, THINKING
& PEOPLE
PROVIDER STANDARD #1147

SOCIETÀ ITALIANA DI PSICHIATRIA


RATIONALE

Schizophrenia spectrum disorders are classified among Severe mental illness (SMI). The chronic nature of these disorders is characterized by recurring episodes, residual symptom burden, and a variable degree of cognitive dysfunction and functional impairment, which may persist even during periods of remission; they represent a major public health issue, accounting for significant health and social and economic burden worldwide.

Second-generation antipsychotic (SGAs), which inhibit dopaminergic D2 receptors and serotonergic 5-HT_{2A} receptors in the brain, have shown efficacy in reducing symptoms of schizophrenia. Anyway, suboptimal adherence to treatment and relapse rates, deriving from different factors –patients' lack of insight into their illness, medication beliefs, substance abuse– are directly related to the patient's functional deterioration.

Other challenges associated with the management of schizophrenia include adverse events, environmental elements, and sometimes the limited efficacy of therapies in relieving symptoms. In this scenario, it is crucial for patients to benefit from new technologies in

long-acting injectable (LAI) antipsychotics development to overcome some of these challenges, and as an effective alternative to oral treatments, which may not be the best choice in patients with poor adherence.



VENUE OF THE EVENT

Nagyterem meeting room at Hungarian Academy of Science
Széchenyi István tér 9, 1051 Budapest, Hungary

Accredited event for **Surgeons – Psychiatrics**

ITALY ACCREDITATION – CME EVENT N° 1147 – 409511

Training objective: 3 – Clinical documentation. Clinical care pathways diagnostic and rehabilitation, assistance profiles – treatment profiles

Information about the number of credits is under evaluation.

EUROPE ACCREDITATION (EACCME)

The Get-A-Long – Unravelling the new role of Long Acting Injectables in Schizophrenia management, BUDAPEST, Hungary 07/04/2024 – 07/04/2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 2.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.


Provider and Scientific Organization



**CULTURE, THINKING
& PEOPLE**
PROVIDER STANDARD #1174

SCIENTIFIC PROGRAM

- 19:00 – 19:15 **Greetings, Introduction and Aims** – Antonio Vita
- 19:15 – 19:35 **Current landscape of Antipsychotics and LAIs: how to address issues and unmet needs** – Celso Arango
- 19:35 – 19:55 **Pharmacological properties of Antipsychotics: a delicate balance** – Edoardo Spina
- 19:55 – 20:15 **From Mechanism of Action to efficacy and clinical practice** – Antonio Vita
- 20:15 – 20:45 **Discussion** – All faculty
- 20:45 – 21:00 **Closing remarks** – Antonio Vita



CHAIRMAN

Antonio Vita – *Brescia, Italy*

SPEAKERS

Celso Arango – *Madrid, Spain*

Edoardo Spina – *Messina, Italy*

Antonio Vita – *Brescia, Italy*



GET A LONG

Unravelling the **new role** of **Long Acting Injectables**
in **Schizophrenia** management

Budapest
7th April 2024
Hungarian Academy
of Science

REGISTRATION

Registration is free but, for
organizational reasons it is mandatory.

You can register by scanning the QR code:



or by clicking on the site
<https://ctpeople.it/getalongbudapest>

*Supported browsers: Google Chrome, Apple
Safari, Mozilla Firefox, Microsoft Edge*

Unrestricted Educational grant

